Eli Lilly reported trial results on October 28, 2026, for its new drug retatrutide.
The trial compared weekly retatrutide with weekly Ozempic 2 mg in adults with type 2 diabetes.
The trial enrolled 1,298 adults whose diabetes was not well controlled on metformin.
A1C fell by 2.2% with both retatrutide doses, against 1.8% with Ozempic.
The higher dose gave 47.4 pounds of average weight loss, against 20.9 pounds with Ozempic.
The 9 mg dose gave 44.3 pounds of average weight loss, or 19.5% of body weight.
Retatrutide acts on GIP, GLP-1, and glucagon, which help control hunger and blood sugar.
Diarrhea and nausea were the most common side effects, and most were mild to moderate.
Stop rates were 4.8% and 7.9% with retatrutide, against 2.7% with Ozempic.
Retatrutide is not approved anywhere, and no one may legally sell it to patients yet.
About 650 patients will stay in a 24-week extension phase to test longer-term safety.
A strong trial result, but full data and regulator review must come before any approval.
Get the full breakdown, key numbers, and what happens next.
Read on Rive News